percutaneous coronary intervention

Cardiac MattersCangrealor is the first FDA-approved P2Y12 inhibitor.
FDA OKs antiplatelet for use during heart procedureFDA has approved cangrelor (Kengreal, The Medicines Company) for reducing the risk of periprocedural thrombotic events in patients undergoing percutaneous coronary intervention.
Can warfarin improve psychotic symptoms?A study suggests that warfarin use may lead to a decrease in and even long-term remission of psychotic symptoms in patients with schizophrenia.
Delay in filling clopidogrel prescription after coronary stent linked to adverse clinical outcomesA delay in filling the first prescription for clopidogrel after coronary stenting is associated with an increased risk of death and myocardial infarction (MI), according to a study published online May 28 in the Journal of the American Heart Association.